Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer.
P. F. Conte
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
V. Guarneri
No relevant relationships to disclose
D. G. Generali
No relevant relationships to disclose
A. Bottini
No relevant relationships to disclose
L. Bazzola
No relevant relationships to disclose
F. Piacentini
No relevant relationships to disclose
F. Artioli
No relevant relationships to disclose
K. Cagossi
No relevant relationships to disclose
G. Bisagni
No relevant relationships to disclose
M. Bagnalasta
Employment or Leadership Position - GlaxoSmithKline
E. Tagliafico
No relevant relationships to disclose
E. Barbieri
No relevant relationships to disclose
L. Cavanna
No relevant relationships to disclose
A. Ravaioli
No relevant relationships to disclose
R. D'Amico
No relevant relationships to disclose
R. Vicini
No relevant relationships to disclose
A. Frassoldati
No relevant relationships to disclose